In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.

Researchers assessed whether venetoclax-obinutuzumab would be safe and effective in fit and unfit patients with previously untreated CLL.

FDA cleared acalabrutinib plus venetoclax as the only all-oral, fixed-dose combination option for first-line, treatment-naïve CLL/SLL. Phase 3 AMPLIFY showed superior PFS versus chemoimmunotherapy, ...

AstraZeneca has secured approval in the US for Calquence (acalabrutinib) plus venetoclax as the first all-oral, fixed-duration regimen to treat adults with chronic lymphocytic leu ...

SAN DIEGO -- Patients with relapsed/refractory mantle cell lymphoma (MCL) lived significantly longer without disease progression with the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta ...

Acute myeloid leukemia (AML) is a particularly aggressive form of blood cancer that usually progresses rapidly if swift and ...

Shorter-duration venetoclax may be as effective as longer-duration treatment in AML and MDS, with no significant impact on overall survival. The study included 53 patients, predominantly male, with a ...

AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic ...

ATLANTA -- Roughly nine of 10 so-called fit patients with chronic lymphocytic leukemia (CLL) achieved undetectable minimal residual disease (MRD) status after treatment with one of two venetoclax ...

Forbes contributors publish independent expert analyses and insights. I cover cancer science, treatments and attitudes. Why I like about Venetoclax is that it derives from science, and that it works.